These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 25954801)

  • 1. Determining the harm-benefit balance of an intervention: for each patient.
    Prescrire Int; 2014 Nov; 23(154):274-7. PubMed ID: 25954801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing harm in resuscitation medicine.
    Ardagh M
    N Z Med J; 1997 Apr; 110(1041):113-5. PubMed ID: 9140410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Appropriate" diagnostic testing: supporting diagnostics with evidence-based medicine and shared decision making.
    Polaris JJ; Katz JN
    BMC Res Notes; 2014 Dec; 7():922. PubMed ID: 25515327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linking evidence-based medicine therapeutic summary measures to clinical decision analysis.
    Djulbegovic B; Hozo I; Lyman GH
    MedGenMed; 2000 Jan; 2(1):E6. PubMed ID: 11104452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The analysis of physicians' work: announcing the end of attempts at in vitro fertilization].
    Santiago-Delefosse M; Cahen F; Coeffin-Driol C
    Encephale; 2003; 29(4 Pt 1):293-305. PubMed ID: 14615699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction--databases and the assessment of complications associated with the treatment of patients with congenital cardiac disease.
    Jacobs JP
    Cardiol Young; 2008 Dec; 18 Suppl 2():1-37. PubMed ID: 19063774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Patients in pre-dialysis: decision taking and free choice of treatment].
    Sarrias Lorenz X; Bardón Otero E; Vila Paz ML
    Nefrologia; 2008; 28 Suppl 3():119-22. PubMed ID: 19018749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature.
    Brett Hauber A; Fairchild AO; Reed Johnson F
    Appl Health Econ Health Policy; 2013 Aug; 11(4):319-29. PubMed ID: 23637054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In the best interest of the patient. Applying this standard to healthcare decision making must be done in a community context.
    Trau JM; McCartney JJ
    Health Prog; 1993 Apr; 74(3):50-6. PubMed ID: 10124676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reporting of harm in randomized controlled trials published in the urological literature.
    Breau RH; Gaboury I; Scales CD; Fesperman SF; Watterson JD; Dahm P
    J Urol; 2010 May; 183(5):1693-7. PubMed ID: 20299044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk communication and shared decision making in the care of patients with osteoporosis.
    Lewiecki EM
    J Clin Densitom; 2010; 13(4):335-45. PubMed ID: 20663701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards better patient care: drugs to avoid in 2014.
    Prescrire Int; 2014 Jun; 23(150):161-5. PubMed ID: 25121155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Best interests in the 'vegetative state'].
    Jox RJ
    Fortschr Neurol Psychiatr; 2011 Oct; 79(10):576-81. PubMed ID: 21989510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to apply results from randomized trials and systematic reviews to individual patient care.
    Hodson EM; Craig JC
    Nephrology (Carlton); 2010 Apr; 15(3):277-80. PubMed ID: 20470294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.